FIBROSING INTERSTITIAL LUNG DISEASE
Clinical trials for FIBROSING INTERSTITIAL LUNG DISEASE explained in plain language.
Never miss a new study
Get alerted when new FIBROSING INTERSTITIAL LUNG DISEASE trials appear
Sign up with your email to follow new studies for FIBROSING INTERSTITIAL LUNG DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for kids with scarred lungs: new drug trial launches
Disease control Recruiting nowThis study tests a medicine called nerandomilast in children aged 2 to 17 with fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and stiff. The goal is to see if the drug is safe and how the body processes it, and to get early signs of whether it …
Matched conditions: FIBROSING INTERSTITIAL LUNG DISEASE
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Frailty and muscle loss may predict outcomes in lung scarring patients
Knowledge-focused Recruiting nowThis study looks at 100 adults aged 65 and older with fibrosing interstitial lung disease, a condition that scars the lungs and shortens life. Researchers will assess frailty and muscle loss (sarcopenia) using questionnaires and tests to see if these factors predict hospital stay…
Matched conditions: FIBROSING INTERSTITIAL LUNG DISEASE
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC